In a prospective study of 396 women with hereditary breast cancer managed with breast conservation, Metcalfe observed a 55% reduction in the risk of ipsilateral recurrence with adjuvant chemotherapy, a 67% reduction in the risk of ipsilateral recurrence with oophorectomy but no impact of tamoxifen on the risk of ipsilateral recurrence